Skip Navigation

Nodular Lymphocyte-predominant Hodgkin Lymphoma Patients Treated in a Randomized Phase II Trial with Either Rituximab or Mosunetuzumab NORM

Brief Summary

Type:
Lymphomas

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT05886036

Study #:
STUDY00160089

Start Date:
Mar 25, 2024

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT05886036

View Complete Trial Details & Eligibility at ClinicalTrials.gov